Report from AGM NeuroVive Pharmaceutical AB (publ) held its

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

May 9, 2014 at 11:30 AM

Report from AGM

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) today, 9 May 2014. A summary of the resolutions follows. All decisions received the required majorities. Adoption and appropriation of profits The Meeting resolved to adopt the presented Income Statement and Balance Sheet, and the Consolidated Income Statement and Consolidated Balance Sheet. The Meeting also resolved to appropriate the company’s profit or loss in accordance with the Board of Directors’ proposal in the Annual Accounts. Additionally, the Meeting resolved that no dividend is paid for the financial year 2013. Discharge from liability The AGM resolved to discharge the Board members and Chief Executive Officer from liability. Fees The Meeting resolved that fees to Board members not employed by NeuroVive but elected by the AGM, and members of the Board of Directors’ various Committees not employed by NeuroVive, shall be payable as follows: · SEK 300,000 to the Chairman of the Board; · SEK 150,000 each to other Board members; · SEK 100,000 to the Chairman of the Audit Committee; · SEK 50,000 each to other members of the Audit Committee; · SEK 40,000 to the Chairman of the Remuneration Committee; · SEK 20,000 each to other members of the Remuneration Committee. The Meeting also resolved that as in the previous year, auditors’ fees are payable in accordance with approved account, on the customary debiting terms. No fees should be payable to Nomination Committee members. The Board Greg Batcheller, Arne Ferstad, Marcus Keep, Helena Levander, Helmuth von Moltke, Boel Flodgren and Anna Malm Bernsten were re-elected Board members. Greg Batcheller was re-elected as Chairman of the Board. Guidelines for remuneration for senior executives The Meeting resolved on guidelines for remuneration for senior executives in accordance with the proposal, see item 12 in the Invitation to the AGM, published on 9 April 2014. Primarily, the guidelines for remuneration and other terms of employment for management imply that the company shall offer its senior executives market compensation, that compensation shall be subject to consultation by a dedicated Remuneration Committee within the Board of Directors, that the relevant criteria shall consist of the senior executive’s responsibility, role, competence and position. Remuneration to senior executives is decided by the Board of Directors, excluding any Board members that are in a position of dependency to the company and management. These guidelines should be applied to new agreements, or amendments to existing agreements reached with senior executives after the guidelines are adopted, and until new, or revised guidelines are set. What is stipulated for NeuroVive applies also to the group, where applicable. Guidlines for the Nomination Committee The AGM resolved that the work of the Nomination Committee for the AGM 2015 should be conducted in accordance with the proposal, see item 13 in the invitation to the AGM published on 9 April 2014. Basically, the guidelines imply that the nomination committee should consist of one member of each of the three largest shareholders. The Chairman of the Nomination Committee shall be that member appointed by the largest shareholder in terms of the number of votes. Information on the members of the Nomination Committee and the shareholders they represent should be published in press releases by no later than six months prior to the following AGM. About NeuroVive NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden. For more information, please contact Chairman of the Board: Greg Batcheller, tel: +46 73 391 9608, greg.batcheller@neurovive.com For media and investor relations questions, please contact: Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 62 21 or ir@neurovive.se It is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård via the contact above. NeuroVive Pharmaceutical AB (publ) Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48, info@neurovive.se NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 9 May 2014, at 5:15 p.m. CET.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kyndryl's Sovereignty Strategy Tackles Digital Resilience

Driving Resilience Amidst Sovereignty Moves Hot off the press, Kyndryl is rolling out a beefed-up strategy to fortify operational resilience in the face of shifting digital sovereignty challenges. I’d say these guys got their fingers firmly on the geopolitical pulse, and they’re not messing around. “Maintaining critical IT operations is fundamental to business...

Four Seasons' New Palau Hub: A Game-Changer for Luxury

Four Seasons Stirs Up the Luxury Travel Scene Alright, every once in a blue moon, you get this kind of roll-out from a hospitality giant that even gets a stone-cold trader to raise an eyebrow. Four Seasons isn't just any hotel chain; it's a heavyweight in the luxury sector. They're pulling the wraps off their new spot in Palau, and it's about as plush as it gets. They're...

Clean Tech's Dual Role: Energy Resilience and Dependency

Technology's Double-Edged Sword in Energy You ever chat with someone about moving your whole life onto solar? Seems greener and cheaper, right? But dive into the numbers, and you'll see it comes with its own set of strings attached. According to a fresh-off-the-press report from S&P Global, clean tech is both a saving grace and a looming liability economically and...

Triller Faces Legal Storm: Investor Action Deadline Looms

Triller Group Inc. Lands in Hot Water Ah, the stock market—it’s like playing poker in a storm. And here we stand, facing the mess Triller Group Inc. has gotten into. Known on the market as NASDAQ:ILLRW, Triller has caught itself in a legal tug-of-war over some nasty allegations. If you held shares during the period between October 16, 2024, and December 29, 2025, you...

Keurig Dr Pepper's Bold $2B Offering: Strategic Shift

Strategic Moves Behind KDP's $2 Billion Offering Walking through all this, Keurig Dr Pepper (NASDAQ:KDP) has set the stage for something big. Yeah, I'm talking about a hefty $2 billion underwritten public offering. It's one of those moves where you're either shaking your head in confusion or nodding in cautious approval. With the coffee behemoth taking this step, let's...

Silicosis Crisis: Legal and Health Ramifications Loom

The Hidden Dangers of Artificial Stone Here's the grim truth. Artificial stone countertops, loved by many for their aesthetics in kitchens and bathrooms, have a dark side that’s becoming increasingly hard to ignore. Loaded with more than 90% respirable crystalline silica, these materials spew out toxic dust when cut or polished. Once that dust gets airborne, workers...

Tigo Energy Lawsuit: Shareholders' Fight for Justice

Energy Optimism or Illusion? Is it a bright future when projections fizzle out faster than a lukewarm coffee on a cold morning? If you snapped up shares of Tigo Energy (NASDAQ: TYGO) thinking you were hitching your wagon to a rising solar star, the latest class action might just feel like a gut punch. Tangled Partnership Promises Let's cut to the core of the issue. Tigo...

Flyers Fundraiser Supports Mental Health Advocacy in NJ and PA

Blockbusters on Ice, Support Beyond the Rink Here's a twist for hockey fans out there: snagging tickets to catch the Philadelphia Flyers might pack more punch off the ice than on it. Why? Because, for every ticket you grab through Digital Elements Group's special link, $5 is pumped straight into the veins of mental health advocacy in New Jersey and Pennsylvania. Pretty...

Universal Music CFO to Speak at Major Tech Conference

UMG Steps into the Spotlight at Morgan Stanley Event Music, money, and technology—it's a compelling trio. Universal Music Group (EURONEXT: UMG) is sending its heavyweights, Matt Ellis and Michael Nash, to the Morgan Stanley European Technology, Media & Telecom Conference on November 18, 2026. This isn't just any run-of-the-mill industry hobnob. We're talking about the...

Untapped $41B VA Loan Potential: Opportunities Missed

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...